Type 2 diabetes affects 537 million adults globally (IDF, 2021). For patients with BMI ≥35, bariatric surgery achieves 70–80% remission — superior to any medication. For lower BMI patients, GLP-1 medications (Ozempic/Wegovy) now achieve 15–22% body weight reduction. Abroad: bariatric surgery costs $4,000–$9,000 versus $15,000–$35,000 in the US. GLP-1 management programmes are available at specialist clinics in Turkey, Thailand, and Czech Republic.
Medically reviewed by Dr. Murat Ustun, M.D., Founder & Medical Director, Flytocure Healthcare.
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterised by insulin resistance and relative insulin deficiency, leading to chronic hyperglycaemia. It is diagnosed by: fasting blood glucose ≥7.0 mmol/L (126 mg/dL); or HbA1c ≥48 mmol/mol (6.5%); or 2-hour glucose ≥11.1 mmol/L after oral glucose tolerance test. T2DM is strongly associated with obesity — 80–85% of T2DM patients are overweight or obese. Remission is defined as HbA1c <48 mmol/mol (6.5%) maintained for ≥3 months off all diabetes medications.
| Category | Criteria | Recommended Treatment |
|---|---|---|
| Well-controlled T2DM | HbA1c <53 mmol/mol (7%) on 1–2 oral agents; BMI 27–34 | Lifestyle optimisation, GLP-1 agonist (Ozempic/Mounjaro), continue oral medication |
| Suboptimal control | HbA1c 53–75 mmol/mol (7–9%) on multiple agents; BMI 30–39 | GLP-1 agonist intensification; consider ESG + GLP-1; bariatric surgery consultation |
| Poorly controlled T2DM | HbA1c >75 mmol/mol (>9%) on insulin + oral agents; BMI ≥35 | Gastric sleeve or bypass — achieves remission in 50–80% of cases |
| T2DM with BMI ≥40 | Any HbA1c level | Bariatric surgery strongly recommended — bypass achieves 70–80% remission |
| T2DM with BMI 30–35 | Any HbA1c, metabolic uncontrolled | Bariatric surgery acceptable per 2022 IDF/IFSO consensus; ESG + GLP-1 alternative |
Yes — bariatric surgery achieves T2DM remission (defined as HbA1c <6.5% off all medications) in 50–80% of patients. Gastric bypass achieves remission in 70–80% at 2 years. Remission durability: 60% maintain remission at 5 years; 40–50% at 10 years. Even in those who do not achieve full remission, medication burden is significantly reduced. The metabolic benefit of bypass occurs rapidly — many patients discontinue insulin within days to weeks, before significant weight loss occurs, confirming a metabolic mechanism beyond caloric restriction.
Some UK private insurers and international health insurance plans (Cigna, AXA) cover bariatric surgery abroad if clinical criteria are met (BMI ≥35 with T2DM or BMI ≥40). US Medicare and Medicaid cover surgery domestically but not abroad. Many patients self-pay abroad and save 65–80% versus domestic pricing. Always check your insurance policy for 'metabolic surgery for diabetes' coverage — terminology matters for claims.
ESG (non-surgical) achieves 25–35% T2DM improvement at 1 year versus 50–80% remission with surgery. ESG is appropriate for BMI 30–35 patients who want a non-surgical approach or are high surgical risk. For BMI ≥35 with poorly controlled T2DM on insulin, surgical bypass or sleeve is strongly preferred given the magnitude of metabolic benefit. Combining ESG with GLP-1 medications (Ozempic/Mounjaro) narrows the gap but still falls short of surgical remission rates.
Browse 507 accredited clinics for Type 2 Diabetes treatment abroad — compare costs, read patient reviews, and get a free personalised quote within 24 hours.